Grade ≥3 AEs with ≥3% incidence
| Adverse event* . | TN ≥65 years (n = 31) . | R/R (n = 101) . | Total (n = 132) . |
|---|---|---|---|
| Hypertension | 7 (23) | 20 (20) | 27 (20) |
| Pneumonia | 2 (6) | 25 (25) | 27 (20) |
| Neutropenia | 1 (3) | 18 (18) | 19 (14) |
| Thrombocytopenia | 1 (3) | 10 (10) | 11 (8) |
| Atrial fibrillation | 2 (6) | 6 (6) | 8 (6) |
| Diarrhea | 5 (16) | 3 (3) | 8 (6) |
| Fatigue | 1 (3) | 5 (5) | 7 (5) |
| Sepsis | 0 | 7 (7) | 6 (5) |
| Cellulitis | 0 | 5 (5) | 5 (4) |
| Dehydration | 0 | 5 (5) | 5 (4) |
| Febrile neutropenia | 0 | 5 (5) | 5 (4) |
| Hyperglycemia | 1 (3) | 4 (4) | 5 (4) |
| Hypokalemia | 1 (3) | 4 (4) | 5 (4) |
| Sinusitis | 0 | 5 (5) | 5 (4) |
| Bacteremia | 0 | 4 (4) | 4 (3) |
| Decreased appetite | 0 | 4 (4) | 4 (3) |
| Decreased lymphocyte count | 1 (3) | 3 (3) | 4 (3) |
| Increased lymphocyte count | 0 | 4 (4) | 4 (3) |
| Leukocytosis | 0 | 4 (4) | 4 (3) |
| Lymphocytosis | 0 | 4 (4) | 4 (3) |
| Syncope | 1 (3) | 3 (3) | 4 (3) |
| Adverse event* . | TN ≥65 years (n = 31) . | R/R (n = 101) . | Total (n = 132) . |
|---|---|---|---|
| Hypertension | 7 (23) | 20 (20) | 27 (20) |
| Pneumonia | 2 (6) | 25 (25) | 27 (20) |
| Neutropenia | 1 (3) | 18 (18) | 19 (14) |
| Thrombocytopenia | 1 (3) | 10 (10) | 11 (8) |
| Atrial fibrillation | 2 (6) | 6 (6) | 8 (6) |
| Diarrhea | 5 (16) | 3 (3) | 8 (6) |
| Fatigue | 1 (3) | 5 (5) | 7 (5) |
| Sepsis | 0 | 7 (7) | 6 (5) |
| Cellulitis | 0 | 5 (5) | 5 (4) |
| Dehydration | 0 | 5 (5) | 5 (4) |
| Febrile neutropenia | 0 | 5 (5) | 5 (4) |
| Hyperglycemia | 1 (3) | 4 (4) | 5 (4) |
| Hypokalemia | 1 (3) | 4 (4) | 5 (4) |
| Sinusitis | 0 | 5 (5) | 5 (4) |
| Bacteremia | 0 | 4 (4) | 4 (3) |
| Decreased appetite | 0 | 4 (4) | 4 (3) |
| Decreased lymphocyte count | 1 (3) | 3 (3) | 4 (3) |
| Increased lymphocyte count | 0 | 4 (4) | 4 (3) |
| Leukocytosis | 0 | 4 (4) | 4 (3) |
| Lymphocytosis | 0 | 4 (4) | 4 (3) |
| Syncope | 1 (3) | 3 (3) | 4 (3) |
Values are n (%).
AEs are listed by preferred term.